Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aldo Scarpa

Showing results (401-410 of 602) with videos related to

Pageof 61
Sort By:
Scientific Reports|May 10, 2018
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinomaMichele Simbolo, Caterina Vicentini, Andrea Ruzzenente, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 26, 2013
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancersMatteo Fassan, Michele Simbolo, Emilio Bria, et al.
British Journal of Cancer|November 17, 2022
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancerGeny Piro, Carmine Carbone, Antonio Agostini, et al.
Cancer Discovery|October 9, 2015
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsAnguraj Sadanandam, Stephan Wullschleger, Costas A Lyssiotis, et al.
Cancers|July 2, 2021
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open QuestionsRita T Lawlor, Paola Mattiolo, Andrea Mafficini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine NeoplasmsMichele Borghesani, Anna Reni, Eleonora Lauricella, et al.
NPJ Precision Oncology|June 30, 2021
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinomaMichelle R Goulart, Jennifer Watt, Imran Siddiqui, et al.
Pancreas|December 2, 2016
Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical DecisionsSara Cingarlini, Silvia Ortolani, Matteo Salgarello, et al.
Advanced Healthcare Materials|March 12, 2024
A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic CancerYing Liu, Babatunde O Okesola, David Osuna de la Peña, et al.
Journal of Clinical Medicine|April 30, 2021
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine NeoplasmsGiovanni Centonze, Vincenzo Lagano, Giovanna Sabella, et al.
Pageof 61

Showing results (401-410 of 602) with videos related to

Sort By:
Pageof 61
Scientific Reports|May 10, 2018
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinomaMichele Simbolo, Caterina Vicentini, Andrea Ruzzenente, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 26, 2013
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancersMatteo Fassan, Michele Simbolo, Emilio Bria, et al.
British Journal of Cancer|November 17, 2022
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancerGeny Piro, Carmine Carbone, Antonio Agostini, et al.
Cancer Discovery|October 9, 2015
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsAnguraj Sadanandam, Stephan Wullschleger, Costas A Lyssiotis, et al.
Cancers|July 2, 2021
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open QuestionsRita T Lawlor, Paola Mattiolo, Andrea Mafficini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine NeoplasmsMichele Borghesani, Anna Reni, Eleonora Lauricella, et al.
NPJ Precision Oncology|June 30, 2021
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinomaMichelle R Goulart, Jennifer Watt, Imran Siddiqui, et al.
Pancreas|December 2, 2016
Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical DecisionsSara Cingarlini, Silvia Ortolani, Matteo Salgarello, et al.
Advanced Healthcare Materials|March 12, 2024
A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic CancerYing Liu, Babatunde O Okesola, David Osuna de la Peña, et al.
Journal of Clinical Medicine|April 30, 2021
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine NeoplasmsGiovanni Centonze, Vincenzo Lagano, Giovanna Sabella, et al.
Pageof 61